Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro

W. Edward Robinson, T. Kawamura, M. K. Gorny, Douglas Lake, J. Y. Xu, Y. Matsumoto, T. Sugano, Y. Masuho, W. M. Mitchell, E. Hersh, S. Zolla-Pazner

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Three of 16 human monoclonal antibodies (hu-mAbs) enhanced human immunodeficiency virus type 1 (HIV-1) infection of MT-2 target cells by means of a mechanism that is dependent on complement. Enhanced infections are characterized by an increase in cytopathic effects and antigen synthesis as well as an increase in the production of progeny virus as detected by release of reverse transcriptase activity and infectious virus into the culture medium. Analyses by radio-immunoprecipitation, Western blot, and ELISA using the pENV9 envelope fragment localize the antigenic specificities of these three hu-mAbs to the N-terminal two-thirds of the transmembrane protein gp41. Competitive binding experiments indicate that the hu-mAbs are reactive with immunodominant epitopes of gp41 recognized by sera from essentially all HIV-1-infected subjects. Combination dose-effect experiments demonstrate that these hu-mAbs can act synergistically in vitro to enhance HIV-1 infection. These data demonstrate that hu-mAbs directed against the HIV-1 transmembrane glycoprotein gp41 can enhance HIV-1 infection in vitro. The availability of these reagents allows for the mapping of enhancing epitopes on HIV-1 and provides a means for studying whether deletion of such enhancing epitopes from candidate HIV-1 vaccines might improve the protective immune response to HIV-1 in immunized humans and chimpanzees.

Original languageEnglish (US)
Pages (from-to)3185-3189
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume87
Issue number8
StatePublished - Apr 1990
Externally publishedYes

Fingerprint

Virus Diseases
HIV-1
Glycoproteins
Monoclonal Antibodies
Epitopes
Viruses
Epitope Mapping
Immunodominant Epitopes
Competitive Binding
Pan troglodytes
In Vitro Techniques
RNA-Directed DNA Polymerase
Radio
Immunoprecipitation
Culture Media
Vaccines
Western Blotting
Enzyme-Linked Immunosorbent Assay
Antigens
Infection

Keywords

  • AIDS
  • Antibody-dependent enhancement
  • Complement
  • Vaccine development

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. / Robinson, W. Edward; Kawamura, T.; Gorny, M. K.; Lake, Douglas; Xu, J. Y.; Matsumoto, Y.; Sugano, T.; Masuho, Y.; Mitchell, W. M.; Hersh, E.; Zolla-Pazner, S.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, No. 8, 04.1990, p. 3185-3189.

Research output: Contribution to journalArticle

Robinson, WE, Kawamura, T, Gorny, MK, Lake, D, Xu, JY, Matsumoto, Y, Sugano, T, Masuho, Y, Mitchell, WM, Hersh, E & Zolla-Pazner, S 1990, 'Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro', Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 8, pp. 3185-3189.
Robinson, W. Edward ; Kawamura, T. ; Gorny, M. K. ; Lake, Douglas ; Xu, J. Y. ; Matsumoto, Y. ; Sugano, T. ; Masuho, Y. ; Mitchell, W. M. ; Hersh, E. ; Zolla-Pazner, S. / Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. In: Proceedings of the National Academy of Sciences of the United States of America. 1990 ; Vol. 87, No. 8. pp. 3185-3189.
@article{91d83f9b99ea4ab4a0cc867dbd433863,
title = "Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro",
abstract = "Three of 16 human monoclonal antibodies (hu-mAbs) enhanced human immunodeficiency virus type 1 (HIV-1) infection of MT-2 target cells by means of a mechanism that is dependent on complement. Enhanced infections are characterized by an increase in cytopathic effects and antigen synthesis as well as an increase in the production of progeny virus as detected by release of reverse transcriptase activity and infectious virus into the culture medium. Analyses by radio-immunoprecipitation, Western blot, and ELISA using the pENV9 envelope fragment localize the antigenic specificities of these three hu-mAbs to the N-terminal two-thirds of the transmembrane protein gp41. Competitive binding experiments indicate that the hu-mAbs are reactive with immunodominant epitopes of gp41 recognized by sera from essentially all HIV-1-infected subjects. Combination dose-effect experiments demonstrate that these hu-mAbs can act synergistically in vitro to enhance HIV-1 infection. These data demonstrate that hu-mAbs directed against the HIV-1 transmembrane glycoprotein gp41 can enhance HIV-1 infection in vitro. The availability of these reagents allows for the mapping of enhancing epitopes on HIV-1 and provides a means for studying whether deletion of such enhancing epitopes from candidate HIV-1 vaccines might improve the protective immune response to HIV-1 in immunized humans and chimpanzees.",
keywords = "AIDS, Antibody-dependent enhancement, Complement, Vaccine development",
author = "Robinson, {W. Edward} and T. Kawamura and Gorny, {M. K.} and Douglas Lake and Xu, {J. Y.} and Y. Matsumoto and T. Sugano and Y. Masuho and Mitchell, {W. M.} and E. Hersh and S. Zolla-Pazner",
year = "1990",
month = "4",
language = "English (US)",
volume = "87",
pages = "3185--3189",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro

AU - Robinson, W. Edward

AU - Kawamura, T.

AU - Gorny, M. K.

AU - Lake, Douglas

AU - Xu, J. Y.

AU - Matsumoto, Y.

AU - Sugano, T.

AU - Masuho, Y.

AU - Mitchell, W. M.

AU - Hersh, E.

AU - Zolla-Pazner, S.

PY - 1990/4

Y1 - 1990/4

N2 - Three of 16 human monoclonal antibodies (hu-mAbs) enhanced human immunodeficiency virus type 1 (HIV-1) infection of MT-2 target cells by means of a mechanism that is dependent on complement. Enhanced infections are characterized by an increase in cytopathic effects and antigen synthesis as well as an increase in the production of progeny virus as detected by release of reverse transcriptase activity and infectious virus into the culture medium. Analyses by radio-immunoprecipitation, Western blot, and ELISA using the pENV9 envelope fragment localize the antigenic specificities of these three hu-mAbs to the N-terminal two-thirds of the transmembrane protein gp41. Competitive binding experiments indicate that the hu-mAbs are reactive with immunodominant epitopes of gp41 recognized by sera from essentially all HIV-1-infected subjects. Combination dose-effect experiments demonstrate that these hu-mAbs can act synergistically in vitro to enhance HIV-1 infection. These data demonstrate that hu-mAbs directed against the HIV-1 transmembrane glycoprotein gp41 can enhance HIV-1 infection in vitro. The availability of these reagents allows for the mapping of enhancing epitopes on HIV-1 and provides a means for studying whether deletion of such enhancing epitopes from candidate HIV-1 vaccines might improve the protective immune response to HIV-1 in immunized humans and chimpanzees.

AB - Three of 16 human monoclonal antibodies (hu-mAbs) enhanced human immunodeficiency virus type 1 (HIV-1) infection of MT-2 target cells by means of a mechanism that is dependent on complement. Enhanced infections are characterized by an increase in cytopathic effects and antigen synthesis as well as an increase in the production of progeny virus as detected by release of reverse transcriptase activity and infectious virus into the culture medium. Analyses by radio-immunoprecipitation, Western blot, and ELISA using the pENV9 envelope fragment localize the antigenic specificities of these three hu-mAbs to the N-terminal two-thirds of the transmembrane protein gp41. Competitive binding experiments indicate that the hu-mAbs are reactive with immunodominant epitopes of gp41 recognized by sera from essentially all HIV-1-infected subjects. Combination dose-effect experiments demonstrate that these hu-mAbs can act synergistically in vitro to enhance HIV-1 infection. These data demonstrate that hu-mAbs directed against the HIV-1 transmembrane glycoprotein gp41 can enhance HIV-1 infection in vitro. The availability of these reagents allows for the mapping of enhancing epitopes on HIV-1 and provides a means for studying whether deletion of such enhancing epitopes from candidate HIV-1 vaccines might improve the protective immune response to HIV-1 in immunized humans and chimpanzees.

KW - AIDS

KW - Antibody-dependent enhancement

KW - Complement

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=0025253117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025253117&partnerID=8YFLogxK

M3 - Article

C2 - 2326277

AN - SCOPUS:0025253117

VL - 87

SP - 3185

EP - 3189

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -